Evidence map›Paper›PMID 28806415›Full record

ArticlePloS one2017

Synthetic mRNA is a more reliable tool for the delivery of DNA-targeting proteins into the cell nucleus than fusion with a protein transduction domain.

Ivan Leontovyc, David Habart, Sarka Loukotova, Lucie Kosinova, Jan Kriz, Frantisek Saudek, Tomas Koblas

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. mRNA-Based Genetic Reprogramming.Molecular therapy : the journal of the American Society of Gene Therapy · 2019
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ivan LeontovycDepartment of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.ORCID http://orcid.org/0000-0003-1610-7796
David HabartDepartment of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Sarka LoukotovaDepartment of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Lucie KosinovaDepartment of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Jan KrizDepartment of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Frantisek SaudekDepartment of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Tomas KoblasDepartment of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Institute of Clinical and Experimental Medicine · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell reprogramming requires efficient delivery of reprogramming transcription factors into the cell nucleus. Here, we compared the robustness and workload of two protein delivery methods that avoid the risk of genomic integration. The first method is based on fusion of the protein of interest to a protein transduction domain (PTD) for delivery across the membranes of target cells. The second method relies on de novo synthesis of the protein of interest inside the target cells utilizing synthetic mRNA (syn-mRNA) as a template. We established a Cre/lox reporter system in three different cell types derived from human (PANC-1, HEK293) and rat (BRIN-BD11) tissues and used Cre recombinase to model a protein of interest. The system allowed constitutive expression of red fluorescence protein (RFP), while green fluorescence protein (GFP) was expressed only after the genomic action of Cre recombinase. The efficiency of protein delivery into cell nuclei was quantified as the frequency of GFP+ cells in the total cell number. The PTD method showed good efficiency only in BRIN-BD11 cells (68%), whereas it failed in PANC-1 and HEK293 cells. By contrast, the syn-mRNA method was highly effective in all three cell types (29-71%). We conclude that using synthetic mRNA is a more robust and less labor-intensive approach than using the PTD-fusion alternative.

Indexed as

Gene Transfer TechniquesAnimalsCell NucleusClone CellsDNAFlow CytometryGenetic EngineeringGreen Fluorescent ProteinsHEK293 CellsHumansIntegrasesProtein DomainsRatsRecombinant Fusion ProteinsReproducibility of ResultsRNA, MessengerCre recombinaseDNAGreen Fluorescent ProteinsIntegrasesRecombinant Fusion ProteinsRNA, Messenger

Identifiers

PMID28806415
PMCPMC5555570
OpenAlexW2746036943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.